A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910